Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$49.45

1.1 (2.28%)

16:06
08/09/18
08/09
16:06
08/09/18
16:06

Puma Biotechnology reports Q2 adjusted EPS (59c), consensus ($1.26)

Reports Q2 revenue $50.8M, consensus $45.67M. "In the second quarter of 2018, we saw strong commercial progress for Puma," said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. "We continued to grow NERLYNX sales in the United States, with net sales of NERLYNX rising approximately 41% from the 2018 first quarter. We were also pleased that the Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for NERLYNX for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union."

  • 09

    Aug

PBYI Puma Biotechnology
$49.45

1.1 (2.28%)

05/04/18
SBSH
05/04/18
NO CHANGE
SBSH
Buy
Puma's Nerlynx can achieve blockbuster status, says Citi
An analysis of 90 oncology drug launches indicates that products with U.S. sales of at least $200M in the first full calendar year have a greater than 50% probability of reaching $1B-plus sales, Citi analyst Yigal Nochomovitz tells investors in a research note. He believes the analysis supports his view that $1.1B of U.S. sales for Nerlynx by 2024 is an achievable goal, based on Puma Biotechnology's 2018 guidance of $175M-$200M. The analyst keeps a Buy rating on the shares.
05/10/18
SBSH
05/10/18
NO CHANGE
SBSH
Puma Biotechnology weakness a buying opportunity, says Citi
05/10/18
SBSH
05/10/18
NO CHANGE
Target $146
SBSH
Buy
Citi says Puma Biotechnology post-earnings selloff 'far overdone'
Citi analyst Yigal Nochomovitz sees several possible explanations for the post-earnings pullback in shares of Puma Biotechnology, including lower apparent demand for Nerlynx in April, the Q1 cumulative discontinuation rate having risen sequentially to 12% from 9% in the prior quarter and the fact that its third-line metastatic trial is being pushed into the second half or perhaps 2019. However, concluding that the Nerlynx launch may be stalling "seems premature," the discontinuation rate data are still "well within" his expectations and the pushback of NALA data should "only be viewed favorably" given that this is perceived by many to be a risky trial, Nochomovitz tells investors. The analyst, who recommends buying on the dip, has a Buy rating and $146 price target on Puma shares.
06/26/18
JPMS
06/26/18
NO CHANGE
Target $80
JPMS
Overweight
Positive CHMP vote a 'clear upside surprise' for Puma, says JPMorgan
JPMorgan analyst Cory Kasimov called the positive CHMP trend vote recommending approval for neratinib a "clear upside surprise" and "much needed piece of very good news" for Puma Biotechnology. Kasimov notes he had fully removed EU sales following the previous initial negative vote in January so a formal positive opinion next month and sales in early 2019 would represent "pure upside" to his estimates. The news should also likely add to neratinib's strategic value, said Kasimov, who keeps an Overweight rating and $80 price target on Puma shares.

TODAY'S FREE FLY STORIES

FLIR

Flir Systems

$49.83

-0.31 (-0.62%)

13:53
03/18/19
03/18
13:53
03/18/19
13:53
Downgrade
Flir Systems rating change  »

Flir Systems downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

RIO

Rio Tinto

$57.03

1.04 (1.86%)

13:49
03/18/19
03/18
13:49
03/18/19
13:49
Periodicals
SEC can pursue Rio Tinto fraud cause, judge says, Reuters reports »

U.S. District Judge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CREE

Cree

$56.77

-0.14 (-0.25%)

13:45
03/18/19
03/18
13:45
03/18/19
13:45
Options
Cree call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

ON

ON Semiconductor

$21.95

-0.23 (-1.04%)

13:39
03/18/19
03/18
13:39
03/18/19
13:39
Hot Stocks
ON Semiconductor has introduced two new silicon carbide, SiC Mosfet devices »

ON Semiconductor has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,180.85

-4.41 (-0.37%)

, GOOGL

Alphabet Class A

$1,184.84

-6.94 (-0.58%)

13:38
03/18/19
03/18
13:38
03/18/19
13:38
Periodicals
Google denies working with Chinese military, NBCNews reports »

Google denied…

GOOG

Alphabet

$1,180.85

-4.41 (-0.37%)

GOOGL

Alphabet Class A

$1,184.84

-6.94 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 27

    Mar

  • 04

    Apr

  • 27

    Oct

13:35
03/18/19
03/18
13:35
03/18/19
13:35
General news
U.S. corporate bond update: a couple of issuers are jumping in »

U.S. corporate bond…

CCI

Crown Castle

$124.05

-1.03 (-0.82%)

13:35
03/18/19
03/18
13:35
03/18/19
13:35
Options
Crown Castle put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
03/18/19
03/18
13:35
03/18/19
13:35
General news
Treasury Option Action: call spread liquidation »

Treasury Option Action:…

FB

Facebook

$159.31

-6.68 (-4.02%)

13:33
03/18/19
03/18
13:33
03/18/19
13:33
Periodicals
Blumenthal wants Facebook probe after live stream of mosque attack, NY Post says »

Senator Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

13:30
03/18/19
03/18
13:30
03/18/19
13:30
Periodicals
U.K. speaker says parliament won't vote again on Brexit deal, WSJ reports »

John Bercow, speaker of…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$281.92

0.61 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNL

Global Net Lease

$18.38

-0.1 (-0.54%)

13:29
03/18/19
03/18
13:29
03/18/19
13:29
Conference/Events
Global Net Lease management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 28

    Mar

  • 15

    Apr

NVRO

Nevro

$44.31

0.56 (1.28%)

13:27
03/18/19
03/18
13:27
03/18/19
13:27
Conference/Events
Nevro management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

NVRO

Nevro

$44.15

0.4 (0.91%)

13:27
03/18/19
03/18
13:27
03/18/19
13:27
Conference/Events
Nevro management to meet with SVB Leerink »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

APYX

Apyx Medical

$7.93

0.005 (0.06%)

13:25
03/18/19
03/18
13:25
03/18/19
13:25
Conference/Events
Apyx Medical management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

T

AT&T

$30.77

0.09 (0.29%)

13:24
03/18/19
03/18
13:24
03/18/19
13:24
Periodicals
Kevin Tsujihara ousted as Warner Bros. CEO, CNBC reports »

Kevin Tsujihara has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 20

    May

CXP

Columbia Property

$21.99

-0.13 (-0.59%)

13:21
03/18/19
03/18
13:21
03/18/19
13:21
Conference/Events
Columbia Property management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

BSX

Boston Scientific

$37.77

-2.38 (-5.93%)

13:20
03/18/19
03/18
13:20
03/18/19
13:20
Options
Quarter million dollar block of calls sold to open in Boston Scientific »

Quarter million dollar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 28

    May

MIK

Michaels

$11.72

0.04 (0.34%)

, DSW

DSW

$25.05

-0.34 (-1.34%)

13:19
03/18/19
03/18
13:19
03/18/19
13:19
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MIK

Michaels

$11.72

0.04 (0.34%)

DSW

DSW

$25.05

-0.34 (-1.34%)

HDS

HD Supply

$42.88

-0.12 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

REGN

Regeneron

$408.15

-6.03 (-1.46%)

, DERM

Dermira

$12.46

5.63 (82.43%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
On The Fly
Dermira rises, Regeneron slips on eczema treatment study results »

Shares of Dermira (DERM)…

REGN

Regeneron

$408.15

-6.03 (-1.46%)

DERM

Dermira

$12.46

5.63 (82.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
03/18/19
03/18
13:16
03/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBCP

Home Bancorp

$36.50

0.59 (1.64%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Hot Stocks
Home Bancorp CEO John Bordelon sells over $232K shares of company stock »

Home Bancorp CEO John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$31.38

0.69 (2.25%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Periodicals
Elanco tells Bloomberg CEO not planing to sell shares at lockup »

Elanco CEO Jeffrey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

APEN

Apollo Endosurgery

$3.29

-0.06 (-1.79%)

13:13
03/18/19
03/18
13:13
03/18/19
13:13
Recommendations
Apollo Endosurgery analyst commentary  »

Piper says Apollo's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    May

  • 28

    May

QQQ

Invesco QQQ Trust

$178.07

0.1542 (0.09%)

13:10
03/18/19
03/18
13:10
03/18/19
13:10
Options
50K Invesco QQQ Jun 188 - 192 call spreads sold at 95c »

50K Invesco QQQ Jun 188 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.